Activated memory CD4(+) T helper cells repopulate the intestine early following antiretroviral therapy of simian immunodeficiency virus-infected rhesus macaques but exhibit a decreased potential to produce interleukin-2 - PubMed (original) (raw)
Activated memory CD4(+) T helper cells repopulate the intestine early following antiretroviral therapy of simian immunodeficiency virus-infected rhesus macaques but exhibit a decreased potential to produce interleukin-2
J J Mattapallil et al. J Virol. 1999 Aug.
Abstract
Using the simian immunodeficiency virus (SIV)-infected rhesus macaque model, we performed a longitudinal study to determine the effect of antiretroviral therapy on the phenotype and functional potential of CD4(+) T cells repopulating intestinal mucosa in human immunodeficiency virus infection. Severe depletion of CD4(+) and CD4(+) CD8(+) T cells occurred in the intestinal mucosa during primary SIV infection. The majority of these cells were of activated memory phenotype. Phosphonate 9-[2-(phosphomethoxypropyl]adenine (PMPA) treatment led to a moderate suppression of intestinal viral loads and repopulation of intestinal mucosa by predominantly activated memory CD4(+) T-helper cells. This repopulation was independent of the level of viral suppression. Compared to preinfection values, the frequency of naive CD4(+) T cells increased following PMPA therapy, suggesting that new CD4(+) T cells were repopulating the intestinal mucosa. Repopulation by CD4(+) CD8(+) T cells was not observed in either jejunum or colon lamina propria. The majority of CD4(+) T cells repopulating the intestinal mucosa following PMPA therapy were CD29(hi) and CD11ahi. A subset of repopulating intestinal CD4(+) T cells expressed Ki-67 antigen, indicating that local proliferation may play a role in the repopulation process. Although the majority of repopulating CD4(+) T cells in the intestinal mucosa were functionally capable of providing B- and T-cell help, as evidenced by their expression of CD28, these CD4(+) T cells were found to have a reduced capacity to produce interleukin-2 (IL-2) compared to the potential of CD4(+) T cells prior to SIV infection. Persistent viral infection may play a role in suppressing the potential of repopulating CD4(+) T cells to produce IL-2. Hence, successful antiretroviral therapy should aim at complete suppression of viral loads in mucosal lymphoid tissues, such as intestinal mucosa.
Figures
FIG. 1
Differential expression of cell adhesion molecules (CD29, CD11a, and β7-integrin) on repopulating CD4+ T cells from intestinal mucosa compared to peripheral blood CD4+ T cells. The histograms show the differential expression of CD29 (VLA-4), CD11a (LFA-1), and β7-integrins on CD4+ T cells in jejunum and colon LPL and PBMC from uninfected rhesus macaques (solid line) and SIV-infected rhesus macaques after 4 weeks of PMPA therapy (broken line). Isolated cells were stained for CD4, CD29, CD11a, and β7-integrin and analyzed by flow cytometry. Analysis gates were set to include CD4+ T cells only to determine the relative fluorescence intensity of CD29, CD11a, and β7-integrin expression. Negative control samples were stained with matched isotype control antibodies.
FIG. 2
Proliferation of intestinal CD4+ T cells following PMPA therapy. Cells isolated from jejunum and colon lamina propria after 4 weeks of PMPA therapy were stained for cell surface expression of CD4, fixed, permeabilized, and stained for the intracellular expression of Ki-67 antigen. Analysis gates were set to include CD4+ T cells only to determine the proportion of CD4+ Ki-67+ T cells. Negative control samples were stained with anti-CD4 antibody followed by intracellular labeling with matched isotype control antibody. PE, phycoerythrin; FITC, fluorescein isothiocyanate.
FIG. 3
The CD4+ T cells repopulating the intestinal mucosa following PMPA therapy exhibited a decreased capacity to produce IL-2 compared to uninfected controls. The capacity of CD4+ T cells from jejunum and colon lamina propria and peripheral blood to produce IL-2 was determined following short-term in vitro stimulation with phorbol myristate acetate and ionomycin. Isolated cells were stained for cell surface expression of CD4, fixed, permeabilized, and stained for the intracellular production of IL-2. Analysis gates were set to include CD4+ T cells only to determine the capacity of CD4+ T cells to produce IL-2. Negative controls samples included cells stained with matched isotype control antibodies and cells stained with anti-CD4 antibody followed by intracellular labeling with matched isotype control antibody. PI, postinfection.
Similar articles
- Role of collagen deposition in lymphatic tissues and immune reconstruction during HIV-1 and SIV infections.
Estes JD. Estes JD. Curr HIV/AIDS Rep. 2009 Feb;6(1):29-35. doi: 10.1007/s11904-009-0005-0. Curr HIV/AIDS Rep. 2009. PMID: 19149994 Review. - CD4(+) T-cell depletion in HIV infection: mechanisms of immunological failure.
Okoye AA, Picker LJ. Okoye AA, et al. Immunol Rev. 2013 Jul;254(1):54-64. doi: 10.1111/imr.12066. Immunol Rev. 2013. PMID: 23772614 Free PMC article. Review.
Cited by
- Severe intestinal barrier damage in HIV-infected immunological non-responders.
Guo XY, Guo YT, Wang ZR, Jiao YM, Hu Y, Fan LN, Cheng RQ, Qu MM, Zhang C, Song JW, Xu RN, Fan X, Xu W, Zhang JY, Bai BK, Linghu EQ, Chen YK, Ma P, Wang FS. Guo XY, et al. Heliyon. 2023 Oct 12;9(10):e20790. doi: 10.1016/j.heliyon.2023.e20790. eCollection 2023 Oct. Heliyon. 2023. PMID: 37876458 Free PMC article. - An emerging prognosis prediction model for multiple myeloma: Hypoxia-immune related microenvironmental gene signature.
Yu Z, Qiu B, Li L, Xu J, Zhou H, Niu T. Yu Z, et al. Front Oncol. 2022 Aug 30;12:992387. doi: 10.3389/fonc.2022.992387. eCollection 2022. Front Oncol. 2022. PMID: 36110952 Free PMC article. - Gut Microbiome Homeostasis and the CD4 T- Follicular Helper Cell IgA Axis in Human Immunodeficiency Virus Infection.
Onabajo OO, Mattapallil JJ. Onabajo OO, et al. Front Immunol. 2021 Mar 19;12:657679. doi: 10.3389/fimmu.2021.657679. eCollection 2021. Front Immunol. 2021. PMID: 33815419 Free PMC article. Review. - Microbial Dysbiosis During Simian Immunodeficiency Virus Infection is Partially Reverted with Combination Anti-retroviral Therapy.
Blum FC, Hardy BL, Bishop-Lilly KA, Frey KG, Hamilton T, Whitney JB, Lewis MG, Merrell DS, Mattapallil JJ. Blum FC, et al. Sci Rep. 2020 Apr 14;10(1):6387. doi: 10.1038/s41598-020-63196-0. Sci Rep. 2020. PMID: 32286417 Free PMC article. - Gender differences in innate responses and gene expression profiles in memory CD4 T cells are apparent very early during acute simian immunodeficiency virus infection.
George J, Johnson RC, Mattapallil MJ, Renn L, Rabin R, Merrell DS, Mattapallil JJ. George J, et al. PLoS One. 2019 Sep 6;14(9):e0221159. doi: 10.1371/journal.pone.0221159. eCollection 2019. PLoS One. 2019. PMID: 31490965 Free PMC article.
References
- Autran B, Carcelain G, Li T S, Blanc C, Mathez D, Tubiana R, Katlama C, Debre P, Leibowitch J. Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science. 1997;277:112–116. - PubMed
- Benmerach A N P, Cerf-Bensussan N. Adhesion molecules on mucosal T lymphocytes. In: Kagnoff M, Kiyono H, editors. Essentials of mucosal immunology. San Diego, Calif: Academic Press, Inc.; 1996. pp. 263–274.
- Biglino A, Pugliese A, Forno B, Pollono A M, Busso M, Gioannini P. Effects of long-term zidovudine treatment on cell-mediated immune response and lymphokine production. J Acquired Immune Defic Syndr. 1991;4:261–266. - PubMed
- Brinchmann J E, Dobloug J H, Heger B H, Haaheim L L, Sannes M, Egeland T. Expression of costimulatory molecule CD28 on T cells in human immunodeficiency virus type 1 infection: functional and clinical correlations. J Infect Dis. 1994;169:730–738. - PubMed
- Clerici M, Landay A L, Kessler H A, Phair J P, Venzon D J, Hendrix C W, Lucey D R, Shearer G M. Reconstitution of long-term T helper cell function after zidovudine therapy in human immunodeficiency virus-infected patients. J Infect Dis. 1992;166:723–730. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- R01 DK043183/DK/NIDDK NIH HHS/United States
- P51 RR000169/RR/NCRR NIH HHS/United States
- RR-00169/RR/NCRR NIH HHS/United States
- R01-DK43183/DK/NIDDK NIH HHS/United States
- R01 AI043274/AI/NIAID NIH HHS/United States
- R01-AI43274/AI/NIAID NIH HHS/United States
LinkOut - more resources
Full Text Sources
Research Materials